These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 26324359)

  • 1. Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.
    Tosoian JJ; Mamawala M; Epstein JI; Landis P; Wolf S; Trock BJ; Carter HB
    J Clin Oncol; 2015 Oct; 33(30):3379-85. PubMed ID: 26324359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB.J Clin Oncol. 2015 Oct 20;33(30):3379-85. [Epub 2015 Aug 31]. doi: 10.1200/JCO.2015.62.5764.
    Scott E; Mamawala M; Epstein JI; Landis P; Wolf S; Trock ; Carter HB
    Urol Oncol; 2017 Mar; 35(3):121-122. PubMed ID: 28159497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
    Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
    Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
    Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
    Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
    Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
    J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
    Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
    J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
    Newcomb LF; Schenk JM; Zheng Y; Liu M; Zhu K; Brooks JD; Carroll PR; Dash A; de la Calle CM; Ellis WJ; Filson CP; Gleave ME; Liss MA; Martin F; McKenney JK; Morgan TM; Tretiakova MS; Wagner AA; Nelson PS; Lin DW
    JAMA; 2024 Jun; 331(24):2084-2093. PubMed ID: 38814624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.
    Nyame YA; Almassi N; Haywood SC; Greene DJ; Ganesan V; Dai C; Zabell J; Reichard C; Arora H; Zampini A; Crane A; Hettel D; Elshafei A; Fareed K; Stein RJ; Berglund RK; Gong M; Jones JS; Klein EA; Stephenson AJ
    J Urol; 2017 Sep; 198(3):591-599. PubMed ID: 28347770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditional probability of reclassification in an active surveillance program for prostate cancer.
    Alam R; Carter HB; Landis P; Epstein JI; Mamawala M
    J Urol; 2015 Jun; 193(6):1950-5. PubMed ID: 25572035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
    Klotz L; Vesprini D; Sethukavalan P; Jethava V; Zhang L; Jain S; Yamamoto T; Mamedov A; Loblaw A
    J Clin Oncol; 2015 Jan; 33(3):272-7. PubMed ID: 25512465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
    Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
    J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.
    Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    JAMA Oncol; 2015 Jun; 1(3):334-40. PubMed ID: 26181182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup.
    Komisarenko M; Wong LM; Richard PO; Timilshina N; Toi A; Evans A; Zlotta A; Kulkarni G; Hamilton R; Fleshner N; Finelli A
    J Urol; 2016 Feb; 195(2):307-12. PubMed ID: 26417646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
    Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
    J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active Surveillance for Favorable Risk Prostate Cancer in African Caribbean Men: Results of a Prospective Study.
    Meunier ME; Eyraud R; Sénéchal C; Gourtaud G; Roux V; Lanchon C; Brureau L; Blanchet P
    J Urol; 2017 May; 197(5):1229-1236. PubMed ID: 27993665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
    Newcomb LF; Thompson IM; Boyer HD; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Ellis WJ; Fazli L; Feng Z; Gleave ME; Kunju P; Lance RS; McKenney JK; Meng MV; Nicolas MM; Sanda MG; Simko J; So A; Tretiakova MS; Troyer DA; True LD; Vakar-Lopez F; Virgin J; Wagner AA; Wei JT; Zheng Y; Nelson PS; Lin DW;
    J Urol; 2016 Feb; 195(2):313-20. PubMed ID: 26327354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
    Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
    Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.
    Musunuru HB; Yamamoto T; Klotz L; Ghanem G; Mamedov A; Sethukavalan P; Jethava V; Jain S; Zhang L; Vesprini D; Loblaw A
    J Urol; 2016 Dec; 196(6):1651-1658. PubMed ID: 27569437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
    Dai C; Ganesan V; Zabell J; Nyame YA; Almassi N; Greene DJ; Hettel D; Reichard C; Haywood SC; Arora H; Zampini A; Crane A; Li J; Elshafei A; Magi-Galluzzi C; Stein RJ; Fareed K; Gong M; Jones JS; Klein EA; Stephenson AJ
    J Urol; 2018 Feb; 199(2):445-452. PubMed ID: 28789947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.